Acute Porphyria Drug Database

L01FG01 - Bevacizumab
Not porphyrinogenic
NP

Rationale
No CYP-affinity. No conceivable effects on PXR activation. However, side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Chemical description
Bevacizumab is a recombinant humanized monoclonal antibody.
Therapeutic characteristics
Bevacizumab is an antineoplastic agent used in the treatment of colorectal cancer with metastases, breast cancer with metastases, advanced lung cancer with metastases. It is administered by IV infusion. Common adverse reactions of bevacizumab that can be confused with an acute porphyric attack are nausea, vomiting, diarrhoea, abdominal pain, and muscle weakness. Side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Metabolism and pharmacokinetics
The metabolism and elimination of bevacizumab is similar to endogenous IgG i.e. primarily via proteolytic catabolism throughout the body, including endothelial cells, and does not rely primarily on elimination through the kidneys and liver.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.

References

  1. Drug reference publications
  2. McEvoy GK, editor. Bevacizumab. The AHFS Drug Information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2009. Electronic version (25.05.10). #2047
  3. Sweetman SC, editor. Martindale: The complete drug reference. Bevacizumab. Pharmaceutical Press 2009. #2049
  4. Summary of Product Characteristics
  5. Norwegian medicines agency. Summary of Product Characteristics (SPC). Avastin. (Last edition: 21.12.09). #2048

Similar drugs
Explore alternative drugs in similar therapeutic classes L01F / L01FG or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙